Poster & Vorträge/oral presentations Kathmann

2002-2005

Kathmann M, Flau K, Schlicker E (2005) Cannabidiol is a negative allosteric modulator at the µ Opioid (MOP) receptor. Naunyn-Schmiedeberg’s Arch Pharmacol 371 [Suppl1]:R35

Malinowska B, Kiec-Kononowicz K, Godlewski G, Flau K, Kathmann M, Zelaszczyk D, Kozlowsk H, Schlicker E (2004) Two bupranolol analogues antagonize atypical ß-adrenoceptors in pithed rats. XVth International Congress of the Polish Pharmacological Society. 12.-14.09.2004, Poznan. Pol J Pharmacol 56 (Suppl), 158

Kathmann M, Schultheiß T, Flau K, Redmer A, Reggio PH, Seltzman HH, Schlicker E (2004) SR141716 increases but VCHSR does not affect transmitter release in guinea-pig hippocampus. Proceedings of the 2004 Symposium on the Cannabinoids, Juny 22-27, 2004, Paestum, Italy, abstract 156

Schultheiß T, Flau K, Redmer A, Kathmann M, Reggio PH, Seltzman HH, Schlicker E (2004) The facilitatory effect of SR141716 on transmitter release is due to its inverse agonist activity at cannabinoid CB1 receptors. Naunyn-Schmiedeberg’s Arch Pharmacol 369 [Suppl1]:R84

Flau K, Redmer A, Liedtke S, Kathmann M, Schlicker E (2003) Potencies and binding affinities of five nociceptin/orphanin FQ receptor antagonists in the mouse brain cortex. Naunyn-Schmiedeberg’s Arch Pharmacol 367 [Suppl]:R38

Kathmann M, Schlicker E, Faulhaber J, Leweke FM (2003) Enhanced mRNA levels of cannabinoid CB2 and CB1 receptors in peripheral blood mononuclear cells from marijuana smokers. Naunyn-Schmiedeberg’s Arch Pharmacol 367 [Suppl]:R76

Redmer A, Kathmann M, Schlicker E (2003) The cannabinoid CB1 receptor-mediated modulation of hippocampal acetylcholine release is preserved in aged mice. Naunyn-Schmiedeberg’s Arch Pharmacol 367 [Suppl]:R24

Flau K, Liedtke S, Kathmann M, Schlicker E, Stark H, Meier G, Schunack W (2002) Does imidazole replacement by a piperidine moiety lead to effective H3-receptor antagonists? Arch Pharm Med Chem 335 [Suppl 1]:P7

Redmer A, Flau K, Liedtke S, Kathmann M, Schlicker E (2002) OP4 receptor-mediated inhibition of noradrenaline and dopamine release in mouse and guinea-pig tissues. Arch Pharm Med Chem 335 [Suppl 1]:P30

Kathmann M, Liedtke S, Schlicker E (2002) CB1 receptor deficiency increases noradrenaline release in the mouse vas deferens. Naunyn-Schmiedeberg’s Arch Pharmacol 365 [Suppl]:R79

Kathmann M, Liedtke S, Flau K, Redmer A, Schlicker E (2002) Further characterization of the cannabinoid receptor inhibiting noradrenaline release in the guinea-pig hippocampus. Proceedings of the 2002 Symposium on the Cannabinoids, July 10-14, 2002, Monteray, CA, USA, abstract 90

Liedtke S, Flau K, Kathmann M, Schlicker E, Stark H, Schunack W (2002) Does imidazoline replacement by a piperidino moiety affect histamine H3-receptor antagonist potency? Naunyn-Schmiedeberg’s Arch Pharmacol 365 [Suppl]:R28

Schlicker E, Liedtke S, Flau K, Kathmann M (2002) Further evidence that the cannabinoid receptor inhibiting noradrenaline release in the guinea-pig brain belongs to the CB1 subtype and is subject to an endogenous tone. XIVth international Congress of Pharmacology 7.-12. July 2002, San Francisco, CA, USA

1999-2001

De Vry J, Eckel G, Schlicker E, Kathmann M (1999) Effects of an antisense oligodeoxynucleotide on behavior and cannabinoid CB1 receptor agonist-induced hypothermia and analgesia in the rat. Behavioural Pharmacology 10 [Suppl 1]: S25

Göthert M, Nickel T, Bauer U, Kathmann M, Schlicker E, Sasse A, Stark H, Schunack W (2001)Two Novel Partial Agonists at the H3Receptor Inhibiting Noradrenaline Release in the Mouse Brain Cortex. The 9th International Catecholamine Symposium. 31.03.-05.04.2001, Kyoto. Abstract p.62

Kathmann M, Göthert M, Schlicker E (1999) An antisense oligodeoxynucleotide decreases CB1 cannabinoid receptor density without affecting acetylcholine release in the rat hippocampus. Naunyn-Schmiedeberg´s Arch Pharmacol 359 [Suppl]: R90

Kathmann M, Haug K, Heils A, Nöthen MM, Schlicker E (2000) Exchange of three amino acids in the cannabinoid CB1 receptor (CNR1) of an epilepsy patient. Naunyn-Schmiedeberg´s Arch Pharmacol 361 [Suppl]: R99

Kathmann M, Haug K, Heils A, Nöthen MM, Schlicker E (2000) Exchange of three amino acids in the cannabinoid CB1 receptor (CNR1) of an epilepsy patient. Proceedings of the 2000 Symposium on the Cannabinoids, June 22-24, 2000, Baltimore, USA, abstract 2

Kathmann M, Nakazi M, Bauer U, Schlicker E (1999) WIN 55,212-2 inhibits serotonin release in the mouse brain cortex via presynaptic cannabinoid CB1 receptors. Proceedings of the 1999 Symposium on the Cannabinoids, June 18-20, 1999, Acapulco, Mexico, abstract 51

Kathmann M, Weber B, Zimmer A, Schlicker E (2001) Enhanced acetylcholine release in the hippocampus of cannabinoid CB1 receptor-deficient mice. Naunyn-Schmiedeberg´s Arch Pharmacol 363 [Suppl]: R24

Kathmann M, Weber B, Zimmer A, Schlicker E (2001) Enhanced acetylcholine release in the hippocampus of cannabinoid CB1-receptor-deficient mice. Proceedings of the 2001 Symposium on the Cannabinoids, June 27-30, 2001, Madrid, Spain, abstract 56

Menzel S, Göthert M, Schlicker E, Kathmann M, Molderings GJ (2000) Agmatine, an endogenous modulator of neurotransmission in rat vena cava. Naunyn-Schmiedeberg´s Arch Pharmacol 361 [Suppl]: R27

Nakazi M, Kathmann M, Schlicker E (1999) Cannabinoid CB1 receptor-mediated inhibition of serotonin release in the mouse brain. Naunyn-Schmiedeberg´s Arch Pharmacol 359 [Suppl]: R89

Nickel T, Bauer U, Kathmann M, Schlicker E, Sasse A, Stark H, Schunack W (2000) Novel histamine H3-receptor antagonists and partial agonists with an aliphatic ether moiety. Naunyn-Schmiedeberg´s Arch Pharmacol 361 [Suppl]: R102

Schlicker E, Godlewski G, Kwolek G, Malinowska B, Kathmann M, Göthert M (2001) Cardiovascular effects of cannabinoids in the rat. Berlin, Germany

Schlicker E, Kathmann M (2000) Modulation of the release of noradrenaline and other transmitters via cannabinoid and opioid receptors. Fund Clin Pharmacol 14:64

Schlicker E, Kathmann M (2000) Modulation of neurotransmitter release via histamine H3 receptors.
European Neuropsychopharmacology 10 [Suppl 3]: S199-S200

Schlicker E, Kathmann M, Weber B, Zimmer A (2001) Disruption of the cannabinoid CB1 receptor gene selectively increases acetylcholine release in the mouse hippocampus. XIV International Congress of the Polish Pharmacological Society, Sept. 10–13., 2001

Schlicker E, Kathmann M, Bauer U, Nickel T, Weber B (2000) Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the rodent: effect of an antisense oligodeoxynucleotide and comparison with other presynaptic receptors. Proceedings of the 2000 Symposium on the Cannabinoids, June 22-24, 2000, Baltimore, USA, abstract 97

1996-1998

Drutel G, Kathmann M, Héron A, Mace S, Gros C, Schwartz JC, Arrang JM (1997) Un nouveau facteur transcriptionnel, Arnt2, á expression neuronale préférentielle dans le cerveau de rat. Congrès des Neuroscience Françaises, Bordeaux 1997

Kathmann M, Göthert M, Schlicker E (1998) Antisense oligodeoxynucleotides decrease density of CB1 cannabinoid receptors in rat hippocampus and striatum. Proceedings of the 1998 Symposium on the Cannabinoids, July 23-25, 1998, La Grande Motte, France, abstract 51

Kathmann M, Göthert M, Schlicker E (1998) Antisense oligodeoxynucleotides decrease density of CB1 cannabinoid receptors in rat hippocampus and striatum. XIIIth international Congress of Pharmacology 26. - 31. July 1998/München, Germany

Kathmann M, Schlicker E, Göthert (1998) NMDA-and Kainate-stimulated noradrenaline release in the guinea-pig hippocampus is modulated by cannabinoid CB1 receptors. Naunyn-Schmiedeberg´s Arch Pharmacol 357 [Suppl]: R90

Nakazi M, Bauer U, Kathmann M, Göthert M, Schlicker E (1998) The stereoselective k opioid receptor antagonist Mr 2266 does not exhibit stereoselectivity as an antagonist at orphan opioid (ORL1) receptors. 7th Winter Meeting of the Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, 7-10 October 1998, Hannover, Germany

Schlicker E, Werthwein S, Kathmann M (1998) Orphan opioid receptor-mediated inhibition of noradrenaline, dopamine and serotonin release in the mouse, rat and guinea-pig brain. Naunyn-Schmiedeberg´s Arch Pharmacol 357 [Suppl]: R90

Schlicker E, Werthwein S, Kathmann M, Göthert M, Lin S, Makriyannis A (1998) A comparison of the cannabinoid CB1 and orphan opioid (ORL1) receptor-mediated inhibition of noradrenaline release in the brain. Proceedings of the 1998 Symposium on the Cannabinoids, July 23-25, 1998, La Grande Motte, France, abstract 31

Werthwein S, Bauer U, Kathmann M, Schlicker E (1998) Nociceptin inhibits noradrenaline release in the mouse brain cortex via presynaptic orphan opioid receptors. XIIIth international Congress of Pharmacology 26. - 31. July 1998/München, Germany

1992-1995

Kathmann M, Schlicker E (1992) Dimaprit, nordimaprit and homodimaprit: affinities for H3 binding sites and antagonistic potencies in a functional H3 receptor model. Naunyn-Schmiedeberg´s Arch Pharmacol 345 [Suppl 2]: R57

Kathmann M, Detzner M, Timmerman H, Schlicker E (1993) Nordimaprit, homodimaprit and clobenpropit: affinities for H3 binding sites and properties at functional H3 receptors. 22nd Annual Meeting of the European Histamine Research Society, 19. - 22.05.1993, Köln. Abstraktband, pp 104

Kathmann M, Schlicker E, Göthert M (1994) Intermediate affinity and potency of clozapine and low affinity of other neuroleptics and of antidepressants at H3 receptors. Naunyn-Schmiedeberg´s Arch Pharmacol 349 [Suppl]: R95

Kathmann M, Schlicker E, Göthert M (1994) Intermediate affinity and potency of clozapine and low affinity of other neuroleptics and of antidepressants at H3 receptors. 1st European Congress of Clinical Neuropharmacology, 12. - 14.05.1994, Freiburg. In: Proceedings of the 1st European Congress of Clinical Neuropharmacology (eds. Lücking CH, Feuerstein TJ), pp 35

Kathmann M, Schlicker E, Reidemeister S, Stark H, Schunack W (1994) Novel histamine H3 receptor antagonists: affinities in an H3 receptor binding assay and potencies in two functional H3 receptor models. 2nd European Congress of Pharmaceutical Sciences, 29.09. - 01.10.1994, Berlin. Eur J Pharmaceutical Sci 2:P86

Leurs R, Kathmann M, Vollinga RC, Menge WMPB, Schlicker E, Timmerman H (1995) The histamine analogue impemtamine discriminates between peripheral and brain histamine H3 receptors. Pharmacol Res 31 [Suppl]:272

Molderings GJ, Kathmann M, Schlicker E, Göthert M (1994) Involvement of presynaptic imidazoline receptors in the modulation of noradrenaline release in the rabbit aorta. J Autonom Pharmacol 14 [Suppl]:22

Schlicker E, Detzner M, Kathmann M, Göthert M (1993) Release-modulating histamine H3 receptors in the mouse brain: an investigation into signal transduction. 22nd Annual Meeting of the European Histamine Research Society, 19. - 22.05. 1993, Köln. Abstraktband, pp 55

Schlicker E, Fink K, Detzner M, Kathmann M (1993) Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. Naunyn-Schmiedeberg´s Arch Pharmacol 347 [Suppl]:R118

Schlicker E, Kathmann M, Stark H, Schunack W (1994) Affinities and potencies at H3 receptors of compounds differing from histamine in the side chain. Naunyn-Schmiedeberg´s Arch Pharmacol 349 [Suppl]: R96

Schlicker E, Kathmann M, Stark H, Schunack W (1994) Affinities and potencies at H3 receptors of compounds differing from histamine in the side chain. New Perspectives in Histamine Research, 20. -24.07.94, Riding Mountain National Park, Canada. Abstraktband, pp 60

Schlicker E, Malinowska B, Kathmann M, Göthert M (1993) Modulation of neurotransmitter release via histamine H3 heteroreceptors. Joint Meeting of the Association des Pharmacologistes and of the Deutsche Gesellschaft für Pharmakologie und Toxikologie, Lille. Fund Clin Pharmacol 7:336